Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
03/2005
03/09/2005CN1192031C Epothilones derivatives, their synthesis and uses
03/09/2005CN1192021C 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands
03/09/2005CN1192018C Cell adhesive-inhibiting anti inflammatory and immune-suppressive compounds
03/09/2005CN1192015C Cell adhesion inhibitors
03/09/2005CN1192014C Method for prepring HIV protease inhibitor
03/08/2005US6864380 Antiinflammatory agents; asthma; antiallergens; autoimmune diseases; antiarthritic agents
03/08/2005US6864368 Muscle relaxants, controlling immunology, sexual disorders, rheumatic diseases
03/08/2005US6864268 Antidiabetic agents
03/08/2005US6864266 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists
03/08/2005US6864265 Chemokine receptor binding heterocyclic compounds
03/08/2005US6864263 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy
03/08/2005US6864249 Pharmaceutical compositions containing them are of the class of thrombin inhibitors which are useful as anticoagulants.
03/08/2005US6863841 Light emitting diodes; thin films transistors
03/03/2005WO2005019214A1 Novel antimicrobial aryloxazolidinone compounds
03/03/2005WO2005019213A1 N-aryl-2-cyanooxazolidinones and their derivatives
03/03/2005WO2005019212A1 Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
03/03/2005WO2005019211A2 Biaryl heterocyclic compounds and methods of making and using the same
03/03/2005WO2005019206A1 Mitotic kinesin inhibitors
03/03/2005WO2005019205A1 Mitotic kinesin inhibitors
03/03/2005WO2005019190A2 (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors
03/03/2005WO2005019184A1 Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
03/03/2005WO2005019177A1 Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
03/03/2005WO2005019168A2 Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
03/03/2005WO2005018672A1 Drug containing chymase inhibitor as the active ingredient
03/03/2005WO2005018644A1 Capped pyrazinoylguanidine sodium channel blockers
03/03/2005WO2005018568A2 Inhibitors of cathepsin s
03/03/2005WO2005018557A2 Substituted pyridinones
03/03/2005WO2005018531A2 Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof
03/03/2005WO2004110350A3 Compouds and uses thereof in modulating amyloid beta
03/03/2005WO2004101553B1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
03/03/2005WO2004083173A3 Ketopiperazine derivatives as bradykinin antagonists
03/03/2005WO2004001058A3 Transcription factor modulating compounds and methods of use thereof
03/03/2005WO2003089418A8 Indane acetic acid derivatives and their use as pharmaceutical agents
03/03/2005US20050049297 Semi-synthetic process for the preparation of N-debenzoylpaclitaxel
03/03/2005US20050049290 Benzimidazole derivatives and their use as gnrh antagonists
03/03/2005US20050049288 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS
03/03/2005US20050049274 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one
03/03/2005US20050049258 Enzyme inhibitors for phosphodiesterase isozymes for treatment of asthma, chronic bronchitis and chronic obstructive pulmonary disease
03/03/2005US20050049247 Pyrimidines useful as modulators of voltage-gated ion channels
03/03/2005US20050049246 Such as [3-(2-Bromo-ethoxy)-phenyl]-[4-(3-cyclohexyl-5-methyl-isoxazol-4-yl)-pyrimidin-2-yl]-amine
03/03/2005US20050049244 osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis
03/03/2005US20050049237 Pyrazole-amides and -sulfonamides
03/03/2005US20050049235 Amino ceramide-like compounds and therapeutic methods of use
03/03/2005US20050048315 Such as 4-(dicyanomethylene)-2-{p-(dialkylamino)styryl}-6-{p-(diarylamino)styryl}-4H-pyran; improved carrier transportation and exhibits long wavelength light
03/03/2005CA2536480A1 Novel antimicrobial aryloxazolidinone compounds
03/03/2005CA2536435A1 Drug containing chymase inhibitor as the active ingredient
03/03/2005CA2536313A1 Fused pyrimidine derivative and use thereof
03/03/2005CA2536253A1 Aminofurazan compounds useful as protein kinase inhibitors
03/03/2005CA2536095A1 Aminobenzimidazole derivatives
03/03/2005CA2535796A1 N-aryl-2-cyanooxazolidinones and their derivatives
03/03/2005CA2528089A1 Biaryl heterocyclic compounds and methods of making and using the same
03/02/2005EP1510518A2 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels
03/02/2005EP1510516A1 Pyrazole compound and medicinal composition containing the same
03/02/2005EP1509518A1 Calcium receptor modulating agents
03/02/2005EP1509509A1 Glucagon antagonists/inverse agonists
03/02/2005EP1509507A2 Mitotic kinesin inhibitors
03/02/2005EP1509499A1 Pyrrole compounds for the treatment of prostaglandin mediated diseases
03/02/2005EP1509224A1 Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
03/02/2005EP1509213A2 Acetamides and benzamides that are useful in treating sexual dysfunction
03/02/2005EP1278741B1 Muscarinic agonists
03/02/2005CN1589270A Indole-2-formamide compounds as factor Xa inhibitors
03/02/2005CN1589261A Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
03/02/2005CN1589260A Heterocyclic compounds and methods of use thereof
03/02/2005CN1191252C 3-position substituted quinolone derivativers and its use in pharmacy
03/02/2005CN1191249C Quinoline and quinazoline compound for treating benign prostatic hyperplasia specially
03/02/2005CN1191239C Pyrazole derivatives for the treatment of viral diseases
03/01/2005US6861533 Solution phase sythesis of arylbenzoxazoles
03/01/2005US6861440 Antidiabetic agents
03/01/2005US6861433 Oxazolidinone photoaffinity probes
03/01/2005US6861432 Piperazine derivatives that destabilize androgen receptors
03/01/2005US6861424 A piperazine compound as antithrombotic agent
03/01/2005US6861418 Modulating protein kinase signal transduction; anticancer agents
02/2005
02/24/2005WO2005017126A2 Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
02/24/2005WO2005016921A2 Novel oxazoles, their manufacture and use as pharmaceutical agents
02/24/2005WO2005016920A1 Pyrrole compositions useful as inhibitors of c-met
02/24/2005WO2005016919A1 Aminopyrones and their use as atm inhibitors
02/24/2005WO2005016918A2 Heterocyclic n-aryl carboxamides as cytokine inhibitors
02/24/2005WO2005016915A1 Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
02/24/2005WO2005016914A1 Chemical compounds
02/24/2005WO2005016897A1 Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds
02/24/2005WO2005016896A1 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators
02/24/2005WO2005016893A2 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
02/24/2005WO2005016888A1 Probe for diseases wth amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change
02/24/2005WO2005016883A2 Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
02/24/2005WO2005016879A2 Cyclic pyrazinoylguanidine sodium channel blockers
02/24/2005WO2005016876A2 Cyclic amine bace-1 inhibitors having a benzamide substituent
02/24/2005WO2005016862A1 Substituted arylalkanoic acid derivative and use thereof
02/24/2005WO2005016384A1 Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
02/24/2005WO2005016346A1 Quinazoline analogs as receptor tyrosine kinase inhibitors
02/24/2005WO2005016338A1 Use of 5-ht2b receptor antagonists for the treatment of congestive heart failure
02/24/2005WO2005016267A2 Oxazole compounds for the treatment of neurodegenerative disorders
02/24/2005WO2004096235A8 Anti-cancer phosphonate analogs
02/24/2005WO2004093789A3 Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
02/24/2005WO2004046103A3 Arylpyridine compounds
02/24/2005US20050043545 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
02/24/2005US20050043542 Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents
02/24/2005US20050043388 Therapy, prevention of metabolism disorders; insulin resistance; antidiabetic agents; hypoglycemic agents; anticholesterol agents; obesity; polycystic ovarian syndrome
02/24/2005US20050043379 Leukotriene hydrolase inhibitors; antiinflammatory agents; antihistamines; chronic onstructive pulmonary disorders; atherosclerosis; multiple sclerosis; inflammatory bowel disorders; antiarthritic agents ;psoriasis
02/24/2005US20050043378 LTA4H modulators
02/24/2005US20050043364 Novel pyrrole-based HMG-CoA reductase inhibitors
1 ... 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 ... 647